ACE-031 and Testosterone Interaction

Monitor
Mechanism-based 46% confidence

ACE-031 and Testosterone have an interaction requiring monitoring for interaction with 46% confidence. Both ACE-031 and Testosterone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Both compounds affect the gonads and heart and liver, so monitoring these systems is recommended.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Half-life: 12-15 days Typical dose: 0.5-3 mg/kg IV every 2 weeks (clinical research doses only) growth hormone, anabolic
actriibmyostatintgf beta androgenicanticoagulantblood pressure raisinghpta suppressive
View full profile

Testosterone

Anabolic-Androgenic Steroid | Primary Male Sex Hormone

Testosterone exerts its effects primarily through binding to the intracellular androgen receptor (AR), forming a hormone-receptor complex that translocates to the nucleus and modulates gene transcription. This drives protein synthesis in skeletal muscle (anabolic effect), stimulates erythropoietin production in the kidneys to increase red blood cell mass, promotes osteoblast activity and bone mineral density, and regulates libido and cognitive function.

Half-life: ~8 days (cypionate) Typical dose: 100-200 mg/week (TRT) anabolic, sexual health, metabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgeniccarcinogenic riskestrogenichematocrit raising
View full profile

Combined Organ Load

Gonads
elevated
Heart
moderate
Liver
low
Pituitary
low
Pancreas
low

Shared Safety Flags

2x 2 androgenic compounds (ACE-031, Testosterone). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 HPTA-suppressive compounds (ACE-031, Testosterone). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (ACE-031, Testosterone). Get lipid panel mid-cycle — consider adding lipid support.
2x 2 compounds share the teratogenic safety flag (ACE-031, Testosterone). Monitor accordingly.

Frequently Asked Questions

Can I take ACE-031 with Testosterone?

Yes, but with caution. Both ACE-031 and Testosterone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and Testosterone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between ACE-031 and Testosterone?

Both ACE-031 and Testosterone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and Testosterone?

ACE-031 has a half-life of 12-15 days and Testosterone has a half-life of ~8 days (cypionate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: ACE-031 vs Testosterone

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.